Sana Biotechnology (NASDAQ:SANA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Sana Biotechnology (NASDAQ:SANA) from a sell rating to a hold rating in a report issued on Saturday,Wall Street Zen reports.

SANA has been the topic of several other reports. TD Cowen upgraded Sana Biotechnology to a “strong-buy” rating in a report on Monday, August 24th. Bank of America dropped their price objective on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a report on Friday, August 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sana Biotechnology in a report on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.60.

Sana Biotechnology Price Performance

Sana Biotechnology stock opened at $2.46 on Friday. Sana Biotechnology has a 1-year low of $2.22 and a 1-year high of $5.49. The firm has a market capitalization of $736.43 million, a P/E ratio of -4.64 and a beta of 2.30. The company’s 50-day moving average is $2.85 and its 200 day moving average is $3.34.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. Research analysts anticipate that Sana Biotechnology will post -0.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sana Biotechnology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SANA. Rockefeller Capital Management L.P. increased its holdings in shares of Sana Biotechnology by 74.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock valued at $39,000 after acquiring an additional 4,088 shares during the period. Royal Bank of Canada lifted its stake in shares of Sana Biotechnology by 76.8% during the 1st quarter. Royal Bank of Canada now owns 12,285 shares of the company’s stock worth $35,000 after purchasing an additional 5,338 shares during the last quarter. Swiss National Bank lifted its stake in shares of Sana Biotechnology by 2.0% during the 1st quarter. Swiss National Bank now owns 342,600 shares of the company’s stock worth $987,000 after purchasing an additional 6,800 shares during the last quarter. Cetera Investment Advisers lifted its stake in shares of Sana Biotechnology by 50.2% during the 1st quarter. Cetera Investment Advisers now owns 26,181 shares of the company’s stock worth $75,000 after purchasing an additional 8,750 shares during the last quarter. Finally, Walleye Capital LLC bought a new stake in Sana Biotechnology during the second quarter valued at about $35,000. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc is a clinical-stage biotechnology company focused on developing engineered cell and gene therapies for serious diseases. The company’s approach is designed to create durable treatments by modifying cells outside or inside the body and using them to replace, repair, or supplement damaged or missing biological functions.

Sana is developing proprietary technologies intended to support the delivery and persistence of therapeutic cells. These include platforms for engineering cells to evade immune-system detection, potentially allowing donor-derived cells to be used without extensive immune suppression, as well as methods for delivering genetic instructions directly to targeted tissues.